Stocktoria

QUEST DIAGNOSTICS INC DGX

NYSE · XNYS · stock · Services-Medical Laboratories
Chart by TradingView
6/9
Piotroski F — financial health
3.52
Altman Z″ — distress risk · safe
35.6%
Dividend payout · safe

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$11.0B$992.0M$1.4B$7.2B
2024$9.9B$871.0M$909.0M$6.8B
2023$9.3B$854.0M$864.0M$6.3B
2022$9.9B$946.0M$1.3B$5.9B
2021$10.8B$2.0B$1.8B$6.5B
2020$9.4B$1.4B$3.6B$1.6B$6.8B

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
KUPPUSAMY KARTHIKSVP, Clinical Solutions2026-06-04Option exercise3,320$127.72
KUPPUSAMY KARTHIKSVP, Clinical Solutions2026-06-04Option exercise4,827$121.81
KUPPUSAMY KARTHIKSVP, Clinical Solutions2026-06-04Sell8,147$200.00
Davis J. E.CEO and President2026-06-01Sell10,000$194.14
CARTER ROBERT Bdirector2026-05-20Grant1,142
Gregg Vicky Bdirector2026-05-20Grant1,142
Diaz Luisdirector2026-05-20Grant1,142
MAIN TIMOTHY Ldirector2026-05-20Grant1,142

Why these scores methodology →

Piotroski F-score: 6/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 3.52 (safe)

  • Working capital / assets 0.006
  • Retained earnings / assets 0.616
  • EBIT / assets 0.096
  • Equity / liabilities 0.792

Source: SEC EDGAR filings · CIK 0001022079 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.